<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31471712</PMID><DateCompleted><Year>2020</Year><Month>11</Month><Day>12</Day></DateCompleted><DateRevised><Year>2020</Year><Month>11</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1590-3478</ISSN><JournalIssue CitedMedium="Internet"><Volume>41</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology</Title><ISOAbbreviation>Neurol Sci</ISOAbbreviation></Journal><ArticleTitle>Effect of edaravone therapy in Korean amyotrophic lateral sclerosis (ALS) patients.</ArticleTitle><Pagination><StartPage>119</StartPage><EndPage>123</EndPage><MedlinePgn>119-123</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10072-019-04055-3</ELocationID><Abstract><AbstractText>Oxidative stress caused by free radicals has been implicated in the pathogenesis of amyotrophic lateral sclerosis (ALS). Edaravone (also known as MCI-186), a free radical scavenger, was approved as an ALS treatment in 2015 in Japan. However, the therapeutic effects of edaravone on patients with ALS outside of Japan are not yet reported. This study aims to investigate effects of edaravone on ALS patients in the Korean population. The study included 22 patients with ALS who were treated with edaravone. Of the 16 patients who finished six cycles of treatment, a mean decline of ALSFRS-R after the treatments was 5.75&#x2009;&#xb1;&#x2009;6.07 points and the average change of FVC was -&#x2009;8.7&#x2009;&#xb1;&#x2009;17.0%. Patients experienced only minor adverse events. This study reports on the open-label study of edaravone on patients in Korea for ALS patients, which showed a modest effect of edaravone in this population of ALS patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Jin-Mo</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Dongguk University College of Medicine, Dongguk University Gyeongju Hospital, Gyeongju, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Sun-Young</ForeName><Initials>SY</Initials><AffiliationInfo><Affiliation>Department of Neurology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Donghwi</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Rehabilitation, Daegu Fatima hospital, Daegu, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Jin-Sung</ForeName><Initials>JS</Initials><Identifier Source="ORCID">0000-0001-5506-9206</Identifier><AffiliationInfo><Affiliation>Department of Neurology, School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, 807 Hoguk-ro, Buk-gu, Daegu, 41944, South Korea. neurojspark@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>08</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Neurol Sci</MedlineTA><NlmUniqueID>100959175</NlmUniqueID><ISSNLinking>1590-1874</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016166">Free Radical Scavengers</NameOfSubstance></Chemical><Chemical><RegistryNumber>S798V6YJRP</RegistryNumber><NameOfSubstance UI="D000077553">Edaravone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077553" MajorTopicYN="N">Edaravone</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016166" MajorTopicYN="N">Free Radical Scavengers</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056910" MajorTopicYN="N" Type="Geographic">Republic of Korea</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALSFS-R</Keyword><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis (ALS)</Keyword><Keyword MajorTopicYN="N">Edaravone</Keyword><Keyword MajorTopicYN="N">Korean ALS</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>4</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>8</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>11</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31471712</ArticleId><ArticleId IdType="pmc">PMC7223963</ArticleId><ArticleId IdType="doi">10.1007/s10072-019-04055-3</ArticleId><ArticleId IdType="pii">10.1007/s10072-019-04055-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown RH, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377:162&#x2013;172. doi: 10.1056/NEJMra1603471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1603471</ArticleId><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Beal MF, Ferrante RJ, Browne SE, Matthews RT, Kowall NW, Brown RH. Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis. Ann Neurol. 1997;42:644&#x2013;654. doi: 10.1002/ana.410420416.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410420416</ArticleId><ArticleId IdType="pubmed">9382477</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikawa M, Okazawa H, Tsujikawa T, et al. Increased oxidative stress is related to disease severity in the ALS motor cortex: a PET study. Neurology. 2015;84:2033&#x2013;2039. doi: 10.1212/WNL.0000000000001588.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000001588</ArticleId><ArticleId IdType="pubmed">25904686</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujisawa A, Yamamoto Y. Edaravone a potent free radical scavenger, reacts with peroxynitrite to produce predominantly 4-NO-Edaravone. Redox Rep. 2016;21:98&#x2013;103. doi: 10.1179/1351000215Y.0000000025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1179/1351000215Y.0000000025</ArticleId><ArticleId IdType="pmc">PMC6837651</ArticleId><ArticleId IdType="pubmed">26196041</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing Group; Edaravone (MCI-186) ALS 19 Study Group Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16:505&#x2013;512. doi: 10.1016/S1474-4422(17)30115-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30115-1</ArticleId><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. World Federation of Neurology Research Group on motor neuron D. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293&#x2013;299. doi: 10.1080/146608200300079536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Amin Lari A, Ghavanini AA, Bokaee HR. A review of electrophysiological studies of lower motor neuron involvement in amyotrophic lateral sclerosis. Neurol Sci. 2019;40:1125&#x2013;1136. doi: 10.1007/s10072-019-03832-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-019-03832-4</ArticleId><ArticleId IdType="pubmed">30877611</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacci ED, Staniewska D, Coyne KS, Boyer S, White LA, Zach N, Pooled Resource Open-Access ALS Clinical Trials Consortium et al. Item response theory analysis of the amyotrophic lateral sclerosis functional rating scale-revised in the pooled resource open-access ALS clinical trials database. Amyotroph Lateral Scler Frontotemporal Degener. 2016;17:157&#x2013;167. doi: 10.3109/21678421.2015.1095930.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2015.1095930</ArticleId><ArticleId IdType="pubmed">26473473</ArticleId></ArticleIdList></Reference><Reference><Citation>Castrillo-Viguera C, Grasso DL, Simpson E, Shefner J, Cudkowwicz ME. Clinical significance in the change of decline in ALSFRS-R. Amyotroph Lateral Scler. 2010;11:178&#x2013;180. doi: 10.3109/17482960903093710.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960903093710</ArticleId><ArticleId IdType="pubmed">19634063</ArticleId></ArticleIdList></Reference><Reference><Citation>Park Jin-Sung, Do Young Woo, Park Jin-Mo, Seok Hung Youl, Park Donghwi. Under-recognized primary spontaneous pneumothorax in ALS: a multicenter retrospective study. Neurological Sciences. 2019;40(12):2509&#x2013;2514. doi: 10.1007/s10072-019-03989-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-019-03989-y</ArticleId><ArticleId IdType="pubmed">31267304</ArticleId></ArticleIdList></Reference><Reference><Citation>Okada M, Yamashita S, Ueyama H, Ishizaki M, Maeda Y, Ando Y. Long-term effects of Edaravone on survival of patients with amyotrophic lateral sclerosis. eNeurologicalSci. 2018;11:11&#x2013;14. doi: 10.1016/j.ensci.2018.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ensci.2018.05.001</ArticleId><ArticleId IdType="pmc">PMC6006910</ArticleId><ArticleId IdType="pubmed">29928711</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo L, Song Z, Li X, et al. Efficacy and safety of edaravone in treatment of amyotrophic lateral sclerosis &#x2013; a systemic review and meta-analysis. Neurol Sci. 2018;40:235&#x2013;241. doi: 10.1007/s10072-018-3653-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-018-3653-2</ArticleId><ArticleId IdType="pubmed">30483992</ArticleId></ArticleIdList></Reference><Reference><Citation>Takei K, Takahashi F, Liu S, Tsuda K, Palumbo J. Post-hoc analysis of randomised, placebo-controlled, double-blind study (MCI186-19) of Edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:49&#x2013;54. doi: 10.1080/21678421.2017.1361443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1361443</ArticleId><ArticleId IdType="pubmed">28872913</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing group on behalf of the edaravone (MCI-186) ALS 18 study group Exploratory double-blind, parallel-group, placebo-controlled study of edaravone (MCI-186) in amyotrophic lateral sclerosis (Japan ALS severity classification: grade 3, requiring assistance for eating, excretion or ambulation) Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:40&#x2013;48. doi: 10.1080/21678421.2017.1361441.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1361441</ArticleId><ArticleId IdType="pubmed">28872915</ArticleId></ArticleIdList></Reference><Reference><Citation>Takei K, Tsuda K, Takahashi F, Hirai M, Palumbo J. An assessment of treatment guidelines, clinical practices, demographics, and progression of disease among patients with amyotrophic lateral sclerosis in Japan, the United States, and Europe. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:88&#x2013;97. doi: 10.1080/21678421.2017.1361445.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1361445</ArticleId><ArticleId IdType="pubmed">28872912</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe H, Atsuta N, Hirakawa A, Nakamura R, Nakatochi M, Ishigaki S, Iida A, Ikegawa S, Kubo M, Yokoi D, Watanabe H, Ito M, Katsuno M, Izumi Y, Morita M, Kanai K, Taniguchi A, Aiba I, Abe K, Mizoguchi K, Oda M, Kano O, Okamoto K, Kuwabara S, Hasegawa K, Imai T, Kawata A, Aoki M, Tsuji S, Nakashima K, Kaji R, Sobue G. A rapid functional decline type of amyotrophic lateral sclerosis is linked to low expression of TTN. J Neurol Neurosurg Psychiatry. 2016;87:851&#x2013;858. doi: 10.1136/jnnp-2015-311541.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2015-311541</ArticleId><ArticleId IdType="pubmed">26746183</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>